New Projects information at Drug Development Technology New and updated information from Projects listed on www.drugdevelopment-technology.com http://www.drugdevelopment-technology.com/ en-us http://www.drugdevelopment-technology.com/ New Projects information at Drug Development Technology http://www.drugdevelopment-technology.com/content/images/logo_big.gif Haegarda for the Preventive Treatment of Hereditary Angioedema http://www.drugdevelopment-technology.com/projects/haegarda-for-the-preventive-treatment-of-hereditary-angioedema/ http://www.drugdevelopment-technology.com/projects/haegarda-for-the-preventive-treatment-of-hereditary-angioedema/ Haegarda® (C1 Esterase Inhibitor) a subcutaneous prophylactic therapy indicated for the prevention of hereditary angioedema (HAE) attacks in adolescent and adult patients. Wed, 12 Jul 2017 23:00:00 GMT Zykadia (Ceritinib) Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) http://www.drugdevelopment-technology.com/projects/zykadia-ceritinib-treatment-metastatic-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/zykadia-ceritinib-treatment-metastatic-non-small-cell-lung-cancer-nsclc/ Zykadia (Ceritinib / LDK378) is an inhibitor of anaplastic lymphoma kinase (ALK) indicated for treatment of non-small cell lung cancer (NSCLC). Thu, 06 Jul 2017 23:00:00 GMT Baxdela™ (delafloxacin) for the Treatment of Acute Bacterial Skin and Skin Structure Infections http://www.drugdevelopment-technology.com/projects/baxdela-delafloxacin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections/ http://www.drugdevelopment-technology.com/projects/baxdela-delafloxacin-for-the-treatment-of-acute-bacterial-skin-and-skin-structure-infections/ Baxdela™ (delafloxacin) is a fluoroquinolone antibiotic drug indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI). The drug was discovered and developed by Melinta Therapeutics in partnership with Lig… Thu, 06 Jul 2017 23:00:00 GMT Mydayis for the Treatment of Attention Deficit Hyperactivity Disorder http://www.drugdevelopment-technology.com/projects/mydayis-for-the-treatment-of-attention-deficit-hyperactivity-disorder/ http://www.drugdevelopment-technology.com/projects/mydayis-for-the-treatment-of-attention-deficit-hyperactivity-disorder/ Mydayis is a CNS stimulant drug indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged 13 years and above. Thu, 29 Jun 2017 23:00:00 GMT Truxima (rituximab) for the Treatment of Cancer http://www.drugdevelopment-technology.com/projects/truxima-rituximab-for-the-treatment-of-cancer/ http://www.drugdevelopment-technology.com/projects/truxima-rituximab-for-the-treatment-of-cancer/ ruxima™ (rituximab) is the first biosimilar monoclonal antibody (mAb) approved for the treatment of haematological cancers, including diffuse large B-cell lymphoma, follicular lymphoma, chronic lymphocytic leukaemia, and rheumatoid arthritis, as well… Thu, 08 Jun 2017 23:00:00 GMT Kevzara (sarilumab) for the Treatment of Rheumatoid Arthritis http://www.drugdevelopment-technology.com/projects/kevzara-sarilumab-for-the-treatment-of-rheumatoid-arthritis/ http://www.drugdevelopment-technology.com/projects/kevzara-sarilumab-for-the-treatment-of-rheumatoid-arthritis/ Kevzara® (sarilumab) is a human monoclonal antibody indicated for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA). Sun, 04 Jun 2017 23:00:00 GMT Tecentriq (atezolizumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) http://www.drugdevelopment-technology.com/projects/tecentriq-atezolizumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ http://www.drugdevelopment-technology.com/projects/tecentriq-atezolizumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ Tecentriq® (atezolizumab) is a monoclonal antibody designed to bind with a protein called PD-L1. Wed, 31 May 2017 23:00:00 GMT Dinutuximab beta for the Treatment of Neuroblastoma http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ http://www.drugdevelopment-technology.com/projects/dinutuximab-beta-for-the-treatment-of-neuroblastoma/ Dinutuximab beta is an anti-GD2 monoclonal antibody indicated for the treatment of neuroblastoma in patients aged one year and above. Thu, 18 May 2017 23:00:00 GMT Alunbrig (brigatinib) for the Treatment of Non-Small Cell Lung Cancer (NSCLC) http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ http://www.drugdevelopment-technology.com/projects/alunbrig-brigatinib-for-the-treatment-of-non-small-cell-lung-cancer-nsclc/ Alunbrig (brigatinib) is a tyrosine kinase inhibitor indicated for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC). Tue, 16 May 2017 23:00:00 GMT Radicava (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) http://www.drugdevelopment-technology.com/projects/radicava-edaravone-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/ http://www.drugdevelopment-technology.com/projects/radicava-edaravone-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/ Radicava™ (edaravone) is a neuroprotective agent indicated for the treatment of amyotrophic lateral sclerosis (ALS). Sun, 14 May 2017 23:00:00 GMT Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC) http://www.drugdevelopment-technology.com/projects/imfinzi-durvalumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ http://www.drugdevelopment-technology.com/projects/imfinzi-durvalumab-for-the-treatment-of-metastatic-urothelial-carcinoma-muc/ Imfinzi™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC). Sun, 07 May 2017 23:00:00 GMT Rydapt (midostaurin) for the Treatment of Acute Myeloid Leukaemia and Systemic Mastocytosis http://www.drugdevelopment-technology.com/projects/rydapt-midostaurin-for-the-treatment-of-acute-myeloid-leukaemia-and-systemic-mastocytosis/ http://www.drugdevelopment-technology.com/projects/rydapt-midostaurin-for-the-treatment-of-acute-myeloid-leukaemia-and-systemic-mastocytosis/ Rydapt® (midostaurin) is a multi-targeted inhibitor of multiple kinases including FMS-like tyrosine kinase 3 mutation-positive (FLT3+) and KIT approved for the treatment of acute myeloid leukaemia (AML) and three types of advanced systemic mastocytos… Tue, 02 May 2017 23:00:00 GMT Ingrezza (valbenazine) for the Treatment of Tardive Dyskinesia http://www.drugdevelopment-technology.com/projects/ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia/ http://www.drugdevelopment-technology.com/projects/ingrezza-valbenazine-for-the-treatment-of-tardive-dyskinesia/ Ingrezza (valbenazine) is first and only US Food and Drug Administration (FDA) approved vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the treatment of adults with Tardive dyskinesia (TD). Mon, 17 Apr 2017 23:00:00 GMT Austedo (deutetrabenazine) for the Treatment of Chorea http://www.drugdevelopment-technology.com/projects/austedo-treatment-chorea/ http://www.drugdevelopment-technology.com/projects/austedo-treatment-chorea/ Austedo™ (deutetrabenazine) is a vesicular monoamine transporter 2 (VMAT 2) inhibitor indicated for the treatment of chorea associated with Huntington’s disease (HD). Tue, 11 Apr 2017 23:00:00 GMT Zejula (niraparib) for the Treatment of Ovarian Cancer http://www.drugdevelopment-technology.com/projects/zejula-niraparib-for-the-treatment-of-ovarian-cancer/ http://www.drugdevelopment-technology.com/projects/zejula-niraparib-for-the-treatment-of-ovarian-cancer/ Zejula™ (Niraparib) is a poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor approved for the treatment of adult patients with ovarian cancer. Sun, 09 Apr 2017 23:00:00 GMT Xadago (safinamide) for the Treatment of Parkinson’s Disease (PD) http://www.drugdevelopment-technology.com/projects/xadago-safinamide-for-the-treatment-of-parkinsons-disease-pd/ http://www.drugdevelopment-technology.com/projects/xadago-safinamide-for-the-treatment-of-parkinsons-disease-pd/ Xadago® (safinamide) is a monoamine oxidase type B (MAO-B) inhibitor indicated for the treatment of Parkinson's disease. Tue, 04 Apr 2017 23:00:00 GMT Translarna (ataluren) for the Treatment of Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) http://www.drugdevelopment-technology.com/projects/translarna-ataluren-for-the-treatment-of-nonsense-mutation-duchenne-muscular-dystrophy-nmdmd/ http://www.drugdevelopment-technology.com/projects/translarna-ataluren-for-the-treatment-of-nonsense-mutation-duchenne-muscular-dystrophy-nmdmd/ Translarna™ (ataluren) is a protein restoration therapy indicated for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). The drug was developed by PTC Therapeutics. Sun, 02 Apr 2017 23:00:00 GMT Tresiba (insulin degludec) for the Treatment of Type 1 and Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/tresiba-insulin-degludec-for-the-treatment-of-type-1-and-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/tresiba-insulin-degludec-for-the-treatment-of-type-1-and-type-2-diabetes/ Tresiba (insulin degludec) is the first, long-acting, human insulin indicated for the treatment of Type 1 and Type 2 diabetes. The drug was discovered and developed by Novo Nordisk. Mon, 27 Mar 2017 23:00:00 GMT Kisqali® (ribociclib) for the Treatment of HR+/HER2- Metastatic Breast Cancer http://www.drugdevelopment-technology.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2--metastatic-breast-cancer/ http://www.drugdevelopment-technology.com/projects/kisqali-ribociclib-for-the-treatment-of-hrher2--metastatic-breast-cancer/ Formerly known as LEE011, Kisqali® (ribociclib) is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor indicated for the treatment of hormone receptor positive, human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer i… Wed, 15 Mar 2017 14:04:00 GMT Qtern (dapagliflozin and saxagliptin) for the Treatment of Type 2 Diabetes http://www.drugdevelopment-technology.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/ http://www.drugdevelopment-technology.com/projects/qtern-dapagliflozin-and-saxagliptin-for-the-treatment-of-type-2-diabetes/ Qtern (dapagliflozin and saxagliptin) is a combination drug with sodium/glucose cotransporter (SGLT) 2 and dipeptidyl peptidase 4 (DPP-4) inhibitors indicated for the treatment of type 2 diabetes. Thu, 09 Mar 2017 00:00:00 GMT